search
Back to results

Study of The Effects of Testosterone in Frail Elderly Men

Primary Purpose

Frailty, Sarcopenia

Status
Completed
Phase
Phase 4
Locations
United Kingdom
Study Type
Interventional
Intervention
Transdermal testosterone gel (Testogel 1% )
Matched transdermal placebo gel
Sponsored by
Manchester University NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Frailty focused on measuring Frailty, Muscle strength, Physical performance, Bone mineral density, Quality of life

Eligibility Criteria

65 Years - undefined (Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria: Frail elderly men (as defined by Freid's criteria of frailty) Community - dwelling men aged 65 years and above Total testosterone ≤12.0 nmol/L or calculated free T≤0.25nmol/L Exclusion Criteria: Carcinoma of prostate Carcinoma of breast PSA >4ng/mL Severe symptomatic benign prostatic hypertrophy (IPSS >21) Active liver disease Renal impairment (serum creatinine >180 mmol/L) Congestive heart failure Unstable ischaemic heart disease Polycythaemia Evidence of systemic disease which may affect muscle/joint function Moderate to severe peripheral vascular disease Moderate to severe chronic obstructive airways disease Alcohol consumption over 30 units per week Medications that interfere with sex steroid metabolism History of stroke causing persistent motor deficit Cognitive deficit Major psychiatric illness Hospital admission in the past 6 weeks Sleep apnoea

Sites / Locations

  • Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

1

2

Arm Description

Transdermal testosterone gel (Testogel 1% )

Matched transdermal placebo gel

Outcomes

Primary Outcome Measures

Lower limb muscle strength at 6 months

Secondary Outcome Measures

Upper limb muscle strength at 6 months
Quality of life at 6 months
Total and regional lean body mass at 6 months
Improvement in physical performance
Bone Mineral Density

Full Information

First Posted
September 11, 2005
Last Updated
August 1, 2018
Sponsor
Manchester University NHS Foundation Trust
Collaborators
University of Manchester, Bayer
search

1. Study Identification

Unique Protocol Identification Number
NCT00190060
Brief Title
Study of The Effects of Testosterone in Frail Elderly Men
Official Title
Study of The Effects of Testosterone on Muscle Function, Physical Performance, Body Composition and Quality of Life in Frail Elderly Men
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
October 2004 (undefined)
Primary Completion Date
December 31, 2008 (Actual)
Study Completion Date
December 31, 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Manchester University NHS Foundation Trust
Collaborators
University of Manchester, Bayer

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study aims to determine the effects of testosterone on muscle function, mobility, activities of daily living and overall quality of life
Detailed Description
Ageing-associated loss of muscle mass and strength is a major cause of physical frailty, disability, morbidity and dependency in the elderly. This is associated with increased falls, fractures, loss of mobility, restricted activities of daily living and increased utilisation of healthcare resources. It is well known that serum testosterone levels fall with advancing age and this may be an important cause for muscle wasting and weakness (sarcopenia). Testosterone replacement increases muscle mass and improves muscle strength in young hypogonadal men. In relatively healthy elderly men, some short-term studies have also shown that testosterone can improve muscle strength. The potential beneficial effects of testosterone supplementation on muscle strength and functional capacity of frail elderly men has so far not been studies and forms the basis of this research. We hypothesise that testosterone supplementation is an effective, safe and economic anabolic intervention in frail elderly men with low circulating testosterone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Frailty, Sarcopenia
Keywords
Frailty, Muscle strength, Physical performance, Bone mineral density, Quality of life

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
262 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Transdermal testosterone gel (Testogel 1% )
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Matched transdermal placebo gel
Intervention Type
Drug
Intervention Name(s)
Transdermal testosterone gel (Testogel 1% )
Other Intervention Name(s)
Testogel 1%
Intervention Description
Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
Intervention Type
Drug
Intervention Name(s)
Matched transdermal placebo gel
Intervention Description
Matched transdermal placebo gel, 50mg/d for 6 months
Primary Outcome Measure Information:
Title
Lower limb muscle strength at 6 months
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Upper limb muscle strength at 6 months
Time Frame
6 months
Title
Quality of life at 6 months
Time Frame
6 months
Title
Total and regional lean body mass at 6 months
Time Frame
6 months
Title
Improvement in physical performance
Time Frame
6 months
Title
Bone Mineral Density
Time Frame
6 months

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Frail elderly men (as defined by Freid's criteria of frailty) Community - dwelling men aged 65 years and above Total testosterone ≤12.0 nmol/L or calculated free T≤0.25nmol/L Exclusion Criteria: Carcinoma of prostate Carcinoma of breast PSA >4ng/mL Severe symptomatic benign prostatic hypertrophy (IPSS >21) Active liver disease Renal impairment (serum creatinine >180 mmol/L) Congestive heart failure Unstable ischaemic heart disease Polycythaemia Evidence of systemic disease which may affect muscle/joint function Moderate to severe peripheral vascular disease Moderate to severe chronic obstructive airways disease Alcohol consumption over 30 units per week Medications that interfere with sex steroid metabolism History of stroke causing persistent motor deficit Cognitive deficit Major psychiatric illness Hospital admission in the past 6 weeks Sleep apnoea
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Professor Frederick CW Wu, MD, FRCP
Organizational Affiliation
Central Manchester and Manchester Children's University Hospitals Trust & The University of Manchester
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dr Martin Connolly, MD, FRCP
Organizational Affiliation
Central Manchester and Manchester Children's University Hospitals Trust
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Professor JA Oldham, PhD
Organizational Affiliation
The University of Manchester
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary
City
Manchester
ZIP/Postal Code
M13 9WL
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
11253156
Citation
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. doi: 10.1093/gerona/56.3.m146.
Results Reference
background
PubMed Identifier
6480814
Citation
Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab. 1984 Nov;59(5):955-62. doi: 10.1210/jcem-59-5-955.
Results Reference
background
PubMed Identifier
10442299
Citation
Clague JE, Wu FC, Horan MA. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Androl. 1999 Aug;22(4):261-5. doi: 10.1046/j.1365-2605.1999.00177.x.
Results Reference
background
PubMed Identifier
11701431
Citation
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1172-81. doi: 10.1152/ajpendo.2001.281.6.E1172.
Results Reference
background
PubMed Identifier
21084399
Citation
O'Connell MD, Roberts SA, Srinivas-Shankar U, Tajar A, Connolly MJ, Adams JE, Oldham JA, Wu FC. Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men? J Clin Endocrinol Metab. 2011 Feb;96(2):454-8. doi: 10.1210/jc.2010-1167. Epub 2010 Nov 17.
Results Reference
derived

Learn more about this trial

Study of The Effects of Testosterone in Frail Elderly Men

We'll reach out to this number within 24 hrs